Internationale Partnersuche

Innovation & Technologie Angebot

UK-based SME offers capabilities in production of difficult recombinant proteins and cell lines to companies, universities and research groups

Country of Origin: United Kingdom
Reference Number: TOUK20180712001
Publication Date: 20 July 2018

Summary

A UK-based SME offers its capabilities in mammalian recombinant protein production and cell line development to companies, research groups and universities. The SME will work with partners to generate difficult to produce proteins and cell lines to further the partner's drug target and drug discovery research. It is envisaged that the partnership will take the form of commercial agreements with technical assistance, manufacturing agreements or technical cooperation agreements.

Description

The process of drug target discovery and therapeutic development often requires the production of relevant proteins and cell lines for research. These can be technically difficult to produce and hard to produce in sufficient quantities, both of which hold this research back. 



A UK-based SME specialises in mammalian recombinant protein production and cell line development, which can be transferred into a third party's current good manufacturing practice compliant setting for use in their research programmes. The SME in particular has expertise with hard-to-manufacture proteins and cell lines.



The UK SME is offering to work with partners from industry, research groups and universities to produce required proteins and cells lines for their research. The SME will produce the protein or cell line with feedback and data from partners on the process and performance of the proteins and cell lines informing the SME's internal development programme. It is envisaged that partnerships will take the form of commercial agreements with technical assistance, manufacturing agreements or technical cooperation agreements depending on the individual situation of the partner.

Advantages and Innovations

The SME's capabilities in recombinant protein and cell line generation have the following advantages:



Expression of difficult proteins in a short time period at uncompromising quality.



Increased amount of protein produced - the SME's stable expression vector system can increase protein expression by up to 200-fold when compared to standard mammalian expression systems.

Stage Of Development

Already on the market

Requested partner

The UK SME is looking to work with other companies as well as research groups and universities working in the field of biotherapeutics and drug target research.



The SME offers its expertise and capabilities in generating difficult to produce recombinant proteins and cell lines to partners. The SME will work with partners on their research projects to produce the specific proteins and cell lines required by their research programmes. The SME would expect to receive input and feedback from partners on the performance of the produced proteins and cell lines to inform the SME's internal development programme. This will enable the SME to expand on the range of proteins and cell lines they can offer to future clients and will enable them to improve quality.



It is envisaged that the partnership will take the form of commercial agreements with technical assistance, manufacturing agreements or technical cooperation agreements. the specific type of agreement will depend on the type of partner, the nature of their research programme and their specific situation.